IMPORTANCE There is growing interest in understanding and addressing factors that govern the decision-making process in multiple sclerosis (MS) care. Therapeutic inertia (TI) is the failure to escalate therapy when goals are unmet. Limited data are available on the prevalence of TI and factors affecting therapeutic decisions in the management of patients with MS worldwide.
Introduction
Multiple sclerosis (MS) is an evolving field, with an increasing number of proven effective therapies. [1] [2] [3] Given the broad spectrum of disease-modifying therapies (DMTs), neurologists may face therapeutic dilemmas when individualizing decisions regarding the most appropriate DMT for their patients. 4, 5 It is challenging to decide on an optimal DMT for an individual patient based on the patient's clinical disease activity, magnetic resonance imaging (MRI) lesion burden, drug availability, adverse effect profile, and patient preferences. 1 Despite the recent advances in MS therapeutics, many patients remain undertreated. 6 Numerous factors contribute to the suboptimal management, including education gaps in both risk management and decision making among treating physicians. 7 The concept of clinical inertia was initially introduced by Phillips et al 8 in 2001, who defined it as lack of therapy escalation when it is clinically indicated. The term clinical inertia was substituted with therapeutic inertia (TI) in 2006 by Okonofua et al. 9 Therapeutic inertia is prevalent not only among patients with MS but also in other chronic conditions, such as diabetes and hypertension. [10] [11] [12] There is growing interest in understanding and addressing factors that govern the decisionmaking process 13, 14 in MS. A particular interest is identifying variables that alter the therapeutic decision making of remaining on the same DMT or escalating to a more effective agent, which can be associated with a possible increase in the risk of serious adverse effects. 1, 2 Factors contributing to TI remain poorly understood. However, the results of some studies 6, 15 suggest that physician-associated factors (eg, low tolerance to uncertainty and aversion to ambiguity) may have a role in the decision-making process. In addition, there is limited understanding of country-specific differences with regard to the prevalence of TI. Accordingly, the primary aim of this study was to compare the prevalence of TI among MS-treating physicians in 4 countries (Canada, Argentina, Chile, and Spain). The secondary aim of the study was to identify factors contributing to TI.
Methods

Study Population
This prospective cohort study was conducted between July 10, 2017, and May 4, 2018, and followed and Argentine Neurological Society, Chilean Society of Neurology, and Spanish Neurological Society).
Each participant received an email with instructions and a link to start the study. Participants not actively involved in patient care or those who followed up a low volume of patients with MS (<12 patients with MS per year) were excluded.
Informed consent was provided online at the beginning of the study by each participant.
Participants received compensation for completing the surveys that is equivalent to US $100. The study was approved by the Research Ethics Board of St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. escalation of therapy; therefore, the failure to do so by the participant was considered as TI. The other 2 cases were designed to detect overtreatment when treatment escalation was not deemed medically necessary. All participants were exposed to the same case scenarios. Details of behavioral experiments in which instruments were used in the assessment of tolerance to uncertainty and risk aversion are described elsewhere. 6, 16, 17 In brief, participants were asked to choose between 2 options of (1) either winning US $400 or $0 when the probability is 50/50 (represented by a blue/red bar) vs (2) an option of unknown probability (represented by a blue/red bar covered by a gray bar) of the same outcome. Participants who favored the known probability of 50/50 were deemed to have aversion to ambiguity, while other participants were considered as having tolerance to uncertainty.
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Risk was assessed by asking participants to provide the minimal amount of US dollars (or healthy years) that they would prefer over a 50/50 chance of winning US $400 (or longer survival with adverse effects of a treatment). The degree of risk aversion of each individual corresponded to the difference of the expected value of the risky option (US $200) minus the participant's response. 16 We also evaluated physicians' tolerance to uncertainty in a patient's care using the Reaction to Uncertainty Test. 17 The test was composed of 5 questions that the respondent rated from 0 to 5, which were summed to give a total score. Higher scores represent a lower tolerance to uncertainty.
Low tolerance to uncertainty was defined as values above the median of the total score. Further details of the protocol are published elsewhere. 18 Responses from case scenarios were analyzed in light of responses from the behavioral components.
Definitions
Disease activity was defined as a clinical relapse that was associated with the presence of one of the following MRI findings: at least 1 gadolinium-enhancing lesion or 5 or more new brain lesions. 19, 20 These thresholds were defined based on prior studies demonstrating in patients receiving interferon beta that risk of treatment failure highly correlates with a clinical relapse and MRI lesions as defined above. 21 Disease progression in MS was defined as at least 1 point of sustained worsening from baseline in the Expanded Disability Status Scale Score.
22
At the time of the study, treatment options for relapsing-remitting MS included first-line therapies (beta interferons, glatiramer acetate, teriflunomide, and dimethyl fumarate), second-line therapy (fingolimod), and third-line therapies (natalizumab and alemtuzumab). 4 Given variation in market approval status of some DMTs among the countries in which the study was conducted, ocrelizumab and cladribine were not included in case scenarios. For this analysis, we used the 3-line treatment escalation scheme according to current clinical practice.
6,23
Outcome Measures
The primary outcome was the prevalence of TI. As in previous studies, 6,24 the TI score was calculated by dividing the number of case scenarios in which participants showed TI by the number of case scenarios that measured TI (n = 8). Higher TI scores indicated greater degrees of TI. The TI score ranged between 0 and 8.
Therapeutic inertia prevalence was defined as the proportion of participants with TI in at least 1 case scenario. The secondary outcome was the identification of factors that contributed to TI.
Statistical Analysis
The primary analysis compared TI between Canada and the other 3 countries combined (ie, Argentina, Chile, and Spain). We included different measures of TI as both continuous and categorical variables to determine the consistency of our results. We used mixed-effects linear and logistic models to assess associations between TI score and TI to determine the association between the participants' baseline characteristics and the primary outcome of interest after accounting for clustering. We included the following explanatory variables: age, sex, specialty, number of patients with MS seen per week, proportion of time devoted to clinical care, coauthor of a peer-reviewed publication in the last year (yes or no), practice setting (academic vs nonacademic), risk aversion, aversion to ambiguity, and physicians' reaction to uncertainty (above or below the median).
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This multicenter study included neurologists practicing at academic and community centers in Canada, Argentina, Chile, and Spain who make therapeutic decisions for patients with MS. To account for unmeasured confounding, we used an E-value estimate and a bootstrapping analysis to compare the β coefficients in the normal, percentile, bias-corrected, and bias-corrected and accelerated 95%
CIs. The E-value is a tool to assess the consequences of unmeasured confounding in observational studies. 25 By comparing the upper 95% CI with the 95% CI of covariates included in the models, the E-value provides an estimate of the residual confounding that could explain an observed association if an unmeasured covariate exists. 25 All tests were 2 tailed, and P values less than .05 were considered statistically significant. The area under the curve was used to assess the discrimination, and the Hosmer-Lemeshow test was used to assess the calibration of the model.
Results
Of 300 neurologists with expertise in MS care who were invited to be part of the study, Participant's risk preferences based on assessments with behavioral instruments are listed in Table 3 . Compared with Canada, participants from the other countries were more risk averse and had a lower tolerance to uncertainty (reflected by higher scores) ( Adjusted TI scores are compared across the studied countries. The vertical bars represent 95% CIs. Estimates were derived from linear regression models after adjustment for age, specialty, number of patients with multiple sclerosis seen per week, years of practice, and aversion to ambiguity.. 1.10-4.82; P = .03). The observed vs predicted TI scores after adjustment for covariates are shown in the eFigure in the Supplement. Details by country are listed in Table 2 . 
Assessment of Unmeasured Confounding
We estimated the E-value using the standardized difference of the mean TI score (point estimate, 0.667; standard error, 0.128; and true association with shift estimate, 0.227). The E-value for the point estimate was 2.35, and the CI was 1.66. All 95% CIs of the β coefficients of covariates were lower than the E-value of 2.35 (eTable 1 in the Supplement), making it unlikely for the results to be due to the association of unmeasured confounders. The bootstrapping analysis showed similarities among the β coefficients within each covariate, suggesting unbiased estimates of the TI scores (eTable 2 in the Supplement).
Discussion
Therapeutic inertia is a well-known phenomenon influencing physicians who manage patients with chronic conditions, including MS. 6 Our study showed that neurologists with expertise in MS from 4 different countries exhibited varying degrees of TI. Overall, TI was present in 72.8% (142 of 195) of participants and altered at least 1 in 5 therapeutic decisions. Therapeutic inertia was 2.3-fold more prevalent among neurologists from Argentina, Chile, and Spain (combined) compared with their Canadian counterparts.
The most important factors associated with TI include a lower expertise in MS care (eg, fewer years of experience and a lower number of patients with MS seen per week), country of practice, and a higher aversion to ambiguity. The mixed multivariable analysis supports the contention that aversion to ambiguity was an independent predictor of the prevalence of TI after accounting for demographic factors, level of expertise, and regional variations. We also found that unmeasured confounders were unlikely to have altered our findings.
The country of primary clinical practice was also identified as an independent predictor of TI.
The observed differences among countries can be partially explained by variations in adherence to published MS management guidelines, 2,26,27 regional differences regarding eligibility and access to 
Conclusions
Our study demonstrates the high prevalence of and factors associated with TI even among neurologists with expertise in MS care. To date, our study is the first to systematically compare TI using identical case scenarios across countries. This study constitutes a first step in understanding the mechanisms of TI and increases awareness of its high prevalence. Our findings may also lead to the development of further studies that assess strategies to reduce TI, which may result in improved outcomes for patients with MS. We propose larger studies to evaluate the potential benefits of educational interventions to ameliorate TI. If proven effective, these strategies could be included in curricula for undergraduate and postgraduate medical programs to improve the existing education gaps of formal training in risk management and decision making.
